Paxlovid is authorized for treatment of mild-to-moderate COVID-19 in adults and pediatric patients 12 years of age and older weighing at least 40 kg. Read More

The agency decision was based on data from an ongoing clinical trial. Read More

The two-dose vaccine should be given at least 28 days apart followed by a booster dose after the primary series, the WHO advised. Read More

The EMA said that it is “important that the EU has a wide array of vaccines and treatments” as the pandemic continues to evolve. Read More

The drug will continue to be closely monitored to assess its effectiveness against emerging SARS-CoV-2 variants. Read More

The FDA granted Novavax’s COVID-19 vaccine emergency authorization in July as a two-dose primary series. Read More

The bivalent vaccine also elicited potent neutralizing antibody responses against the Omicron subvariants BA.4 and BA.5 compared to the Spikevax booster, Moderna said. Read More

The company aims to further develop breath-based testing as a “non-invasive way to address major healthcare challenges.” Read More

The agency said that the products pose a risk of false results. Read More

The test is authorized for detection of antigens from the SARS-CoV-2 virus in nasal swab specimens. Read More

The test has not yet been approved, cleared or authorized for use in the U.S. Read More

Lilly said the drug will be available in the week of Aug.15, before the anticipated depletion of the U.S. government’s currently available supply. Read More